Vascular and neoplastic risk in a large cohort of patients with polycythemia vera

Journal of Clinical Oncology

Volumn 23, Issue 10, 2005, Pages 2224-2232

  Marchioli, Roberto ^a   Finazzi, Guido ^a   Landolfi, Raffaele ^a   Kutti, Jack ^a   Gisslinger, Heinz ^a   Patrono, Carlo ^a   Marilus, Raphael ^a   Villegas, Ana ^a   Tognoni, Gianni ^a   Barbui, Tiziano ^a  

^a

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSULFAN; CALCIUM ANTAGONIST; CHLORAMBUCIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYUREA; HYPOCHOLESTEROLEMIC AGENT; INTERFERON; NITRATE; PIPOBROMAN; PLACEBO;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; LEUKEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASIA; MYELOFIBROSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME; VEIN THROMBOSIS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL; THROMBOSIS; TIME;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOSIS; TIME FACTORS;

EID: 20244389579     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.062     Document Type: Article

References (23)

1. Wasserman LR, Berk PD, Berlin NI: Polycythemia vera and the myeloproliferative disorders. Philadelphia, PA, W.B. Saunders, 1995
2. Spivak JL: Polycythemia vera: Myths, mechanisms, and management. Blood 100: 4272-4290, 2002
3. Chievitz E, Thiede T: Complications and causes of death in polycythemia vera. Acta Med Scand 172:513-523, 1962
4. Berk PD, Goldberg JD, Silverstein MN, et al: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441-447, 1981
5. Pearson TC, Messinezy M, Westwood N, et al: A polycythemia vera update: Diagnosis, pathobiology, and treatment, in Schechter GP, Berlinen N, Telen MJ (eds): Hematology 2000 American Society of Hematology Education Program Book. Washington, DC, American Society of Hematology, 2000, pp 51-68
6. Berk PD, Goldberg JD, Donovan PB, et al: Therapeutic recommendations in polycythemia vera based in Polycythemia Vera Study Group Protocols. Semin Hematol 23:132-143, 1986
7. Gilbert HS: Historical perspective on the treatment of essential thrombocythemia and polycythemia vera. Semin Hematol 36:19-22, 1999
8. Landolfi R, Marchioli R, Kutti J, et al: Efficacy and Safety of low-dose aspirin in polycythemia vera: Results of the European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) trial. N Engl J Med 350, 114-124, 2004
9. Gruppo Italiano Studio Policitemia: Low-dose aspirin in polycythemia vera: A pilot study. Br J Haematol 97:453-456, 1997
10. Landolfi R, Marchioli R: European Collaboration on Low-dose Aspirin in Polycythemia vera (ECLAP): A randomized trial. Semin Thromb Hemost 23:473-478, 1997
11. Gruppo Italiano Studio Policitemia: Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 123:656-664, 1995
12. Marchioli R, Barbui T, Landolfi R, et al: Feasibility of randomised clinical trials in rare diseases: The case of polycythemia vera. Leuk Lymphoma 22:121-127, 1996
13. Bennett JM, Catovsky D, Daniel MT, et al: Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 103:620-625, 1985
14. Bennett JM, Catovsky D, Daniel MT, et al: Proposal for the classification of myelodysplastic syndromes. Br J Haematol 51:189-199, 1982
15. Berlin N, Berlin NI: Polycythemia vera. Hematol Oncol Clin North Am 17:1191-1210, 2003
16. Rozman C, Giralt M, Feliu E, et al: Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 67:2658-2663, 1991
17. Brodmann S, Passweg JR, Gratwohl A, et al: Myeloproliferative disorders: Complications, survival and causes of death. Ann Hematol 79: 312-318, 2000
18. Passamonti F, Malabarba L, Orlandi E, et al: Polycythemia vera in young patients: A study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 88:13-18, 2003
19. Landolfi R, Marchioli R, Patrono C: Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Hemost 78:617-621, 1997
20. Pearson T, Whetherley-Mein G: Vascular occlusive episodes and venous hematocrit in primary proliferative polycythemia vera. Lancet 2:1219-1223, 1978
21. Dameshek W: Physiopathology and course of polycythemia vera as related to therapy. JAMA 142:790-797, 1950
22. Streiff MB, Smith B, Spivak JL: The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group. Blood 99:1144-1149, 2002
23. Prchal JT: Elevated hematocrit, risk of thrombosis, and polycythemia vera. Blood 101: 4229, 2003 2233-2239